KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Working Capital Changes (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Working Capital Changes for 15 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 36.12% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.2 million, a 31.9% decrease, with the full-year FY2025 number at $13.2 million, down 31.9% from a year prior.
  • Other Working Capital Changes was $6.9 million for Q4 2025 at Supernus Pharmaceuticals, down from $11.1 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $28.2 million in Q2 2023 to a low of -$20.4 million in Q3 2023.
  • A 5-year average of $935882.4 and a median of -$728000.0 in 2024 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 3603.48% in 2023; the steepest drop was 1556.33% in 2023.
  • Supernus Pharmaceuticals' Other Working Capital Changes stood at -$4.7 million in 2021, then tumbled by 97.87% to -$9.2 million in 2022, then increased by 15.22% to -$7.8 million in 2023, then surged by 238.52% to $10.8 million in 2024, then crashed by 36.12% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Working Capital Changes are $6.9 million (Q4 2025), $11.1 million (Q3 2025), and $2.5 million (Q2 2025).